BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-16 out of 16 found
  Current Search:  tardive: 3, dyskinesia: 21, movement: 1331     

HTML
56%
Santhera's FJORD Phase IIb Study Demonstrates Efficacy of JP-1730/Fipamezole for the Treatment of Dyskinesia i
- Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today positive data from its Phase IIb study (FJORD).

The key finding of the trial is that JP-1730/ fipamezole...

Pharma Live:  Jul 1 2009 1:48AM
Matching: dyskinesia movement
Find similar documents
HTML
56%
Clinical Data Presented at International Congress Showed Treatment With Neupro(R) (rotigotine) Significantly I
- Data Presented at the 13th International Congress of Parkinson's Disease and Movement Disorders - Long-term Treatment With rotigotine was Generally Well Tolerated in Patients With Early Stage Parkinson's...
Pharmacy Choice:  Jun 14 2009 12:14PM
Matching: dyskinesia movement
Find similar documents
HTML
56%
Zonisamide Safe and Effective in Long-Term Treatment of Parkinson's Disease: Presented at MDS
my personal edition> parkinson's > news E-Mail this DGDispatch to a colleague DGDispatch PARIS -- June 12, 2009 -- Long-term treatment with zonisamide is safe and effective in controlling the symptoms of Parkinson's disease (PD...
Doctors Guide:  Jun 13 2009 8:14PM
Matching: dyskinesia movement
Find similar documents
HTML
56%
Patients Treated With Preladenant for Parkinson's Disease Experience Reduced 'Off' Time and Increased 'On' Tim
my personal edition> parkinson's > news E-Mail this DGDispatch to a colleague DGDispatch PARIS -- June 12, 2009 -- Preladenant controls symptoms associated with 'wearing off' in patients with moderate to severe Parkinson's...
Doctors Guide:  Jun 13 2009 8:15PM
Matching: dyskinesia movement
Find similar documents
HTML
56%
Zonisamide Safe and Effective in Long-Term Treatment of Parkinson's Disease: Presented at MDS
-- Long-term treatment with zonisamide is safe and effective in controlling the symptoms of Parkinson's disease (PD) in patients, without those patients developing disabling dyskinesia, researchers reported here at the Movement...
PSL Group:  Jun 12 2009 7:26PM
Matching: dyskinesia movement
Find similar documents
HTML
80%
Tardive dyskinesia associated with aripiprazole;
_ Tardive dyskinesia associated with aripiprazole;.
Facts & Comparisons:  Jun 11 2009 3:55AM
Matching: tardive dyskinesia
Find similar documents
HTML
56%
Resting Tremor Among Several Factors Associated With the Development, Severity of Levodopa-Induced Dyskinesia:
-- The development and severity of levodopa (L-dopa)-induced dyskinesia (LID) in patients with Parkinson's disease (PD) is associated not only by treatment with L-dopa but also with several factors of the patient's PD progression,...
Doctors Guide:  Jun 11 2009 5:23AM
Matching: dyskinesia movement
Find similar documents
HTML
56%
Use of aripiprazole in tardive dyskinesia: An open label study of six cases
(Click the title below to leave the MDLinx Network and go to the Journal's Website) World Journal of Biological Psychiatry, 06/10/09 Print Save in My Library Free Abstract Rajarethinam R et al.

- The study supports our hypothesis that...

MDLinx:  Jun 11 2009 8:28AM
Matching: dyskinesia movement
Find similar documents
HTML
56%
Why are some Parkinson's disease patients unaware of their dyskinesias?
Study of whether anosognosia for dyskinesias in PD results from a failure to detect discrepancies between intended and actual movement Investigation of the ability to detect a discrepancy between intended movement and...
MDLinx:  Jun 10 2009 10:50AM
Matching: dyskinesia movement
Find similar documents
HTML
56%
FDA panel to vote on antipsychotic drugs for kids
ADELPHI, Md.

- A Food and Drug Administration advisory committee will vote Wednesday on whether the makers of three blockbuster antipsychotic drugs already widely prescribed 'off-label' to children and teens should be allowed to market...

USA Today:  Jun 10 2009 1:29AM
Matching: dyskinesia movement
Find similar documents
HTML
64%
Bipolar Disorder and Dopamine Dysfunction: An Indirect Approach Focusing on Tardive Movement Syndromes in a Na
_ Bipolar Disorder and Dopamine Dysfunction: An Indirect Approach Focusing on Tardive Movement Syndromes in a Na.
Abstracts in Hematology and Oncology:  Jun 6 2009 8:49AM
Matching: tardive movement
Find similar documents
HTML
64%
Bipolar Disorder and Dopamine Dysfunction: An Indirect Approach Focusing on Tardive Movement Syndromes in a Na
_ Bipolar Disorder and Dopamine Dysfunction: An Indirect Approach Focusing on Tardive Movement Syndromes in a Na.
Medscape:  Jun 4 2009 9:22PM
Matching: tardive movement
Find similar documents
HTML
56%
Effects of selective serotonin reuptake inhibitors on motor neuron survival
Anderson LB et al.

- Recently tardive dyskinesia, as well as other movement disorders, have been found to be a clinical side effect of SSRIs.

Motor neurons were challenged with fluoxetine and paroxetine at clinically relevant...

MDLinx:  May 29 2009 12:15PM
Matching: dyskinesia movement
Find similar documents
HTML
56%
Biovail to acquire tetrabenazine rights from Cambridge Labs
Biovail Corporation's wholly-owned subsidiary has entered into a definitive agreement to acquire worldwide development and commercialization rights to the entire portfolio of tetrabenazine products, including Xenazine/Nitoman (tetrabenazine...
PharmaBiz:  May 20 2009 8:46AM
Matching: dyskinesia movement
Find similar documents
HTML
56%
Biovail Announces Acquisition of Worldwide Rights to Tetrabenazine
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE:BVF - News) (TSX:BVF - News) today announced a wholly owned subsidiary has entered into a definitive agreement to acquire worldwide development and commercialization rights to the entire...
Business Wire via Yahoo!:  May 18 2009 12:49PM
Matching: dyskinesia movement
Find similar documents
HTML
56%
UPDATE 1-US panel partly backs wider use of AstraZeneca drug
(Adds panel member quote, background) SILVER SPRING, Md., April 8 (Reuters) - AstraZeneca Plc's (AZN.L The committee of Food and Drug Administration advisers said the drug appeared safe when added to other medicines to fight depression.
Reuters:  Apr 8 2009 9:06PM
Matching: dyskinesia movement
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.